Among patients who showed a response, one patient (4.8 mg/kg) with a diagnosis of hormone receptor-negative, HER2-positive breast cancer and lymph node metastasis showed a duration of response lasting approximately 2 years, and the treatment is still continuing. This evidence concerns the gene ERBB2 and metastatic malignant neoplasm in the lymph nodes.